Adaptimmune治疗公共 ADAP 深 沪
等待开盘 07-19 09:30:00 美东时间
0.2795
+0.003
+1.08%
华盛通- 最 高0.2865
- 今 开0.27
- 成交量 60.81万股
- 最 低 0.2683
- 昨 收 0.2765
- 总市值 7406.75万
- 52周最高 1.48
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 0.1951
- 委 比 -66.67%
- 总股本 2.65亿
- 历史最高 21.57
- 量 比 1.67
- 振 幅 6.58%
- 历史最低 0.1951
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adaptimmune Settles Litigation with M.D. Anderson Cancer Center
Adaptimmune Therapeutics ( ($ADAP) ) has issued an announcement. On July 16, 20...
07-18 05:03
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
06-27 00:56
Mizuho Downgrades Adaptimmune Therapeutics to Neutral, Lowers Price Target to $0.5
Mizuho analyst Graig Suvannavejh downgrades Adaptimmune Therapeutics (NASDAQ:ADAP) from Outperform to Neutral and lowers the price target from $1.5 to $0.5.
06-26 22:56
Aptevo Therapeutics Reports 85% Remission Rate In Frontline AML With Mipletamig Combination, No Dose-Limiting Toxicities, Enables Transplant In Previously Ineligible Patient; Advances High-Dose Cohort Enrollment In RAINIER Trial
85% remission rate observed in evaluable frontline AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among evaluable
06-18 20:04
SA Asks: Which oncology companies are attractive M&A targets?
Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology (NASDA...
05-31 03:00
Adaptimmune’s Annual Meeting Focuses on Shareholder Engagement
Adaptimmune Therapeutics ( ($ADAP) ) has issued an update. Adaptimmune Therapeu...
05-30 04:41
LAIRD SUPERFOOD® EXPANDS FUNCTIONAL MUSHROOM PRODUCT LINE AS CONSUMER DEMAND FOR ADAPTOGENS INCREASES
Inspired by Ancient Medicine and Modern Convenience, Six New Mushroom Powders Join Laird Superfood Portfolio BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Laird Superfood, Inc. (NYSE American...
05-15 02:12
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $0.46
Barclays analyst Peter Lawson maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Underweight and lowers the price target from $1 to $0.46.
05-14 22:45
